Leuject

Cladribine, the active ingredient in Leuject, is a purine nucleoside analog (antineoplastic) presented as a subcutaneous formulation for injection use. It functions as an immunosuppressant and antineoplastic agent, indicated for conditions such as multiple sclerosis, hairy cell leukemia, and chronic lymphocytic leukemia, where it selectively reduces pathogenic lymphocytes.

GNH USA supplies Leuject as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, oncology centres, and pharmacies worldwide under strict quality standards and regulatory compliance, and ensuring reliable delivery across global markets.

Cladribine is used in disease‑modifying therapy for immune‑mediated and hematologic conditions. - Multiple sclerosis: reduces relapse frequency and slows disability progression by depleting autoreactive lymphocytes. - Hairy cell leukemia: induces remission by targeting malignant B‑cell clones. - Chronic lymphocytic leukemia: achieves disease control through lymphocyte depletion and apoptosis induction.

Cladribine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Flu-like symptoms: fever, chills, and fatigue. - Nausea or vomiting. - Transient lymphopenia. - Injection site reactions: redness or mild pain.

Serious or Rare Side Effects: - Severe infections: opportunistic or bacterial infections due to profound immunosuppression. - Secondary malignancies: rare reports of new cancers. - Autoimmune disorders: potential emergence of autoimmune hepatitis or thyroiditis.

When prescribing cladribine, clinicians should consider several precautionary measures to minimize risk. - Screen for active infections: treat before initiating therapy. - Monitor lymphocyte counts: regular blood tests to detect prolonged depletion. - Assess vaccination status: administer required vaccines prior to treatment. - Avoid live vaccines during and after therapy until immune reconstitution. - Renal or hepatic impairment: adjust monitoring as metabolism may be affected. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Cladribine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Live attenuated vaccines: may cause uncontrolled infection. - Potent immunosuppressants (e.g., high‑dose corticosteroids, cyclophosphamide): increase risk of severe immunosuppression. - Antiviral agents that inhibit deoxycytidine kinase: may reduce activation of cladribine.

Moderate Interactions (Monitor Closely): - Vaccines (non‑live): efficacy may be reduced; monitor immune response. - Renal excretion modifiers (e.g., probenecid): may alter drug clearance. - Hepatotoxic drugs: combined liver stress warrants liver function monitoring.